Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Tardive Dyskinesia
Interventions: TDtect; Other
Lead sponsor: iRxReminder; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Brooklyn, New York • Garfield Heights, Ohio

Conditions: Tardive Dyskinesia
Interventions: Two way video assessment; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Generalized Anxiety Disorder, Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Mentally Ill Persons
Interventions: iOTA SMI, Health Education Control; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Psychotropic Drugs, Psychiatric Drugs, Children, Shared Decision Making, Patient Decision Aid
Interventions: AWARE Shared Decision Making Medication Review; Behavioral
Lead sponsor: Glyn Jones-Elwyn; Other
Eligibility: 6 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Hanover, New Hampshire • Lebanon, New Hampshire • Auburn, New York + 1 more

Conditions: Autism Spectrum Disorders, Mood Disorders, Sleep Disorders, Attention Deficit Disorders
Interventions: Pharmacological Intervention; Drug
Lead sponsor: Child Psychopharmacology Institute; Other
Eligibility: 6 Months and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Schizophrenia
Interventions: Pimavanserin, Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 33
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Negative Symptoms of Schizophrenia
Interventions: Roluperidone, risperidone, aripiprazole, olanzapine, Placebo; Drug
Lead sponsor: Minerva Neurosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Bellflower, California • Culver City, California • Garden Grove, California + 10 more

Conditions: Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
Interventions: Treatment as usual (TAU), Paliperidone ER; Drug
Lead sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 21
States / cities: Cerritos, California • Chino, California • Garden Grove, California + 18 more

Conditions: Schizoaffective Disorder, Psychotic Disorder
Interventions: Placebo, Paliperidone ER; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 15
States / cities: Cerritos, California • Costa Mesa, California • Garden Grove, California + 12 more

Conditions: Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
Interventions: Olanzapine-samidorphan + exercise; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Patient-centered computerized tool, Written educational materials; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation; Drug
Lead sponsor: Vanguard Research Group; Other
Eligibility: 18 Years to 35 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 39
States / cities: Tucson, Arizona • Granada Hills, California • Palo Alto, California + 35 more

Conditions: Schizophrenia
Interventions: BI 409306 100 mg QD, BI 498306 50 mg QD, Placebo, BI 498306 25 mg QD, BI 409306 10 mg QD; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 18 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: salsalate; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Deutetrabenazine Oral Capsule; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Schizophrenia
Interventions: Placebo, RO4917838, Antipshychotics (Standard of Care); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 27
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more

Conditions: Accidental Fall
Interventions: Gait and balance assessment, Medication review, Comorbidity review, Fall history, Assessment of feet/footwear, Assessment of visual acuity, Home safety risk assessment, Vitamin D Deficiency; Behavioral
Lead sponsor: National Opinion Research Center; Other
Eligibility: 65 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Weight Gain
Interventions: lorcaserin, Intensive dietary counseling; Drug · Behavioral
Lead sponsor: Southern California Institute for Research and Education; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: MEM 3454, Placebo for MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 44
States / cities: Lemon Grove, California • Newport Beach, California • Oceanside, California + 29 more

Conditions: Schizophrenia
Interventions: Pimavanserin, Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 33
States / cities: Phoenix, Arizona • Rogers, Arkansas • Bellflower, California + 27 more

Conditions: Psychosis
Interventions: Lumateperone, Risperidone; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Autism Spectrum Disorder
Interventions: Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID], Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 12 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Lawrence, Kansas • White Plains, New York

Conditions: Schizophrenia
Interventions: iloperidone; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 59
States / cities: Birmingham, Alabama • Cerritos, California • Costa Mesa, California + 46 more

Search by objective public record fields.

Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

The Assessment of Movement Disorders Utilizing Live Two-Way Video

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

Interactive Obesity Treatment Approach (iOTA) for Obesity Prevention in Serious Mental Illness

Decreasing Harms and Improving Child Health

Multidimensional Measurement of Psychopharmacological Treatment Response

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Exercise and Olanzapine-samidorphan

A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

Salsalate as an Adjunctive Treatment for Patients With Schizophrenia

Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

Evaluating the Cost Effectiveness of STEADI

Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

Switching to Iloperidone From Other Antipsychotics in Schizophrenia